Evaluation of the cytotoxic effect and molecular mechanisms associated with the sensitivity to the tyrosine kinase inhibitor
dasatinib in a panel of melanoma cell lines established from metastatic tissue. Identification of markers to select melanoma patients
who would benefit from dasatinib therapy.